Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
(NYSE: PFE) and Roche (OTC: RHHBY) have disappointed investors this year. Pfizer's shares have dropped more than 39% this year, and it's trading near its 52-week low. Roche has seen its stock drop by 19% and just hit a 52-week low on Oct. 19.
Their share drops could represent a good buying opportunity for investors. These pharmaceutical companies have been around for more than a century and have strong track records of revenue growth, reliable dividends, and an emphasis on research and development to fuel new drug development. Which one is the better long-term choice? Let's see.
The drop in Pfizer's stock is not a surprise. Due to a decline in COVID-19-related sales, the New York City-based company's revenue has fallen sharply. It also just cut its yearly sales and profit forecast.
Source Fool.com
Pfizer Inc. Aktie
Die Community bevorzugt Pfizer Inc., mit deutlich mehr Buy- (29) als Sell-Einschätzungen (4).
Ein Kursziel von 41 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 28.07 € bedeuten.
